Searched for
GSPIRIVA
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...
- Buy, Sell or Hold: Citi keeps a buy on Torrent Pharmaceuticals; Morgan Stanley maintains overweight on Reliance IndustriesBrokerages remain positive on select stocks, with Citigroup maintaining a buy rating on Torrent Pharmaceuticals and Morgan Stanley keeping ...
- Buy, Sell or Hold: Nuvama maintains buy on NBCC India; Citi recommends buy on BELBrokerages see opportunities in defence, pharma, and infrastructure. Nuvama backs NBCC India with a target of Rs 139. Citi remains bullish ...
- Lupin shares jump 6% after Kotak Equities’ double upgrade, target price at Rs 1,805Kotak Equities highlights that Lupin has a bunch of products lined up, which will ensure a limited earnings dip in FY2027E after a strong F...
- Hot Stocks: Brokerage view on Page Industries, Zomato, Lupin and ITCMacquarie maintained an underperform rating on Zomato with a target price of Rs 76. The company has seen steady margin improvements and str...
- Fundamental Radar: Sales of this single drug can take Lupin’s US revenue to $1 billion in FY-26Lupin's focus on the US portfolio is to increase dollar sales to above $200 million from the earlier range of $170-190 million. Lupin recen...
- Hot Stocks: Brokerage view on Lupin, Godrej Consumer, Aarti Industries and Bata IndiaMorgan Stanley maintained an overweight rating on Aarti Industries with a target price of Rs 575. Agrochemicals make up one-third of Aarti'...
- Hot Stocks: Brokerage view on Delhivery, Bank of Baroda, Lupin, SBI and M&MDelhivery can sustain strong 18-20% revenue CAGR for a long period of time. Over the medium term, the brokerage firm sees adjusted EBIT mar...
- Lupin shares fall over 4%. Should you buy, sell or hold? Here's what brokerages sayLupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferies, Kotak, and Bernstein maintained...
- Hot Stocks: Brokerages on Shriram Finance, Paradeep Phosphates, L&T and LupinJefferies upgraded Shriram Finance to "buy" and retained a "buy" rating on L&T while Antique initiated a "buy" on Paradeep Phosphates. Kota...
- Hot Stocks: Brokerages on HPCL, Manappuram Finance, Dr Lal Pathlabs and LupinJefferies maintained an underperform rating on Hindustan Petroleum Corporation Limited (HPCL) citing weak marketing and transitory refining...
- Q3 results impact: Tata Motors, Zomato among over 35 stock upgrades and downgradesA team of analysts from global brokerage firm Jefferies has raised the FY23 earnings estimates for 47% of 147 companies under its coverage ...
- Analysts bearish on 'expensive' Lupin after Q3 disappoints, stock falls 9%Of the 44 analysts, 18 of them have a 'sell' rating while 15 remain neutral. On aggregate, analysts slashed consensus price targets by 4.35...
- Sell Lupin, target price Rs 575: JM FinancialLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 31616.79 Crore) operating in Pharmaceuticals s...
- Buy Lupin, target price Rs 1100: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 36549.22 Crore) operating in Pharmaceuticals s...
Load More
